Recursion Pharmaceuticals Raises $60M

Salt Lake City-based Recursion Pharmaceuticals has raised $60 in a Series B funding, the company said this morning, in a round led by Data Collective. The round also included Lux Capital, Obvious Ventures, Advantage Capital, Felicis, Epic, AME plus new investor Mubadala, Menlo Ventures, CRV, Two Sigma, along with angels. Recursion Pharmaceuticals is combining biological sciences with artificial intelligence software for the drug discovery market. Chris Gibson is Co-Founder and CEO of Recursion. As part of the funding, Zachary Bogue, Managing Partner of Data Collective (DCVC), will join the company's board.